Cargando…
间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议（2021年版）
Anaplastic lymphoma kinase (ALK) fusion gene, as a tumor driver gene, was crucial for the occurrence and development of non-small cell lung cancer (NSCLC). Recently, targeted ALK fusion gene has become the main treatment method for ALK-positive NSCLC. The first and second generation ALK inhibitors (...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695243/ https://www.ncbi.nlm.nih.gov/pubmed/34670356 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.32 |